Last reviewed · How we verify
NCT06742203
WPMDE1 - Whey Protein Milk-Derived Exosomes Among Healthy Subjects
NA trial testing Whey Protein Milk-Derived EVs in IBD in 13 participants. Completed in 1 April 2024.
1 March 2024
Quick facts
| Lead sponsor | Exosomm Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 1 October 2023 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Whey Protein Milk-Derived EVs
Conditions studied
- IBD — all drugs for IBD →
Sponsor
Exosomm Ltd.
Who can join
Adults 18 to 60, any sex, with IBD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase 1, single-center, open-label study aims to evaluate the tolerability and usability of WPMDE1, a whey protein milk-derived exosome (EV) nutritional supplement, in healthy adults. The study will assess dose tolerability and determine the appropriate dosage for future studies targeting patients with Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications.
Prabhu MR, Upadhya D, Madhyastha H, Naha A, et al · · 2026 · PMID 41709314 · DOI 10.1186/s12951-026-04058-1 -
Endoplasmic reticulum stress and exosomes secretion in the pathogenesis of inflammatory bowel disease: a concise summary of research findings.
Shibili P A, Banerjee A, Chakraborty S, Kondaveeti SB, et al · · 2025 · PMID 41383462 · DOI 10.3389/fphar.2025.1702825 -
Oral natural extracellular vesicles for biomedical applications: Advances and clinical perspectives.
Guan X, Zhu M, Zhu H, Wang Q, et al · · 2026 · PMID 40783070 · DOI 10.1016/j.jare.2025.08.003
Verify or expand the search:
- PubMed search for NCT06742203
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IBD
Currently open trials in the same condition.
- NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
- NCT07271264 — A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endo · NA · recruiting
- NCT07224113 — Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD · recruiting
- NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
- NCT07380022 — Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Def · NA · recruiting
Other Exosomm Ltd. trials
Trials by the same sponsor.
- NCT06755021 — Whey Protein Milk-Derived Exosomes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06742203 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Exosomm Ltd.
- Last refreshed: 31 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742203.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing